The Daily Biotech Pulse: Inovio's Partner Scales Back R&D Collaboration, Genmab Seeks Nasdaq Listing, Bayer Gets Breakthrough Therapy Designation

Here’s a roundup of top developments in the biotech space over the last 24 hours.

Scaling The Peaks

(Biotech stocks hitting 52-week highs on May 28)

Adverum Biotechnologies Inc (NASDAQ: ADVM) Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) Eidos Therapeutics Inc (NASDAQ: EIDX) Fate Therapeutics Inc (NASDAQ: FATE) Insulet Corporation (NASDAQ: PODD) Milestone Pharmaceuticals Inc (NASDAQ: MIST) Down In The Dumps

(Biotech stocks hitting 52-week lows on May 28)

Abeona Therapeutics Inc (NASDAQ: ABEO) Adamis Pharmaceuticals Corp (NASDAQ: ADMP) Akebia Therapeutics Inc (NASDAQ: AKBA) Alkermes Plc (NASDAQ: ALKS) Allena Pharmaceuticals Inc (NASDAQ: ALNA) ANCHIANO THERAP/S ADR (NASDAQ: ANCN) Aptinyx Inc (NASDAQ: APTX) Aquestive Therapeutics Inc (NASDAQ: AQST) Arbutus Biopharma Corp (NASDAQ: ABUS) Bellicum Pharmaceuticals Inc (NASDAQ: BLCM) Cidara Therapeutics Inc (NASDAQ: CDTX) Endo International PLC (NASDAQ: ENDP) Harvard Bioscience, Inc. (NASDAQ: HBIO) Heat Biologics Inc (NASDAQ: HTBX) Kezar Life Sciences Inc (NASDAQ: KZR)(reacted to negative safety and efficacy data for KZR-616) Melinta Therapeutics Inc (NASDAQ: MLNT) Mylan NV (NASDAQ: MYL) (reacted to generic drug lawsuit) Myriad Genetics, Inc. (NASDAQ: MYGN) Opko Health Inc. (NASDAQ: OPK) Seres Therapeutics Inc (NASDAQ: MCRB) Spring Bank Pharmaceuticals Inc (NASDAQ: SBPH) Teva Pharmaceutical Industries Ltd (NYSE: TEVA) (reacted to generic drug lawsuit) Theravance Biopharma Inc (NASDAQ: TBPH) Stock In Focus Inovio Says AstraZeneca Subsidiary Discontinues Most R&D Collaborations

Inovio Pharmaceuticals Inc (NASDAQ: INO) said in a filing with the SEC it has received notification from AstraZeneca plc (NYSE: AZN)’s MedImmune unit that it intends to discontinue activities with respect to the research collaboration programs, other than MEDI0457.

The two parties will continue to pursue the development of MEDI0457 and AstraZeneca continues to evaluate MEDI0457 in combination with its PD-L1 checkpoint inhibitor durvalumab in multiple Phase 2 trials in patients with cancers associated with HPV.

Inovio’s stock fell 16.56 percent to $2.62 in after-hours trading.

Bayer Gets

Read More Here...

Bookmark the permalink.